Bachelor of Science

Appointment of Chief Financial Officer

Retrieved on: 
Wednesday, March 13, 2024

In 2023, following the acquisition of Kensington Mortgages by Barclays, Marc was appointed as Managing Director, CFO of Kensington Mortgages.

Key Points: 
  • In 2023, following the acquisition of Kensington Mortgages by Barclays, Marc was appointed as Managing Director, CFO of Kensington Mortgages.
  • Marc has a BSc in Management Studies from the University of Manchester and an MBA from the University of London.
  • Marc Page will be required to accumulate a shareholding equivalent of 200% of salary over five years.
  • Further details will be disclosed in the Directors’ Remuneration Report within the Company’s Annual Report and Accounts as appropriate.

Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth

Retrieved on: 
Monday, March 11, 2024

LEXINGTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Hyku Biosciences, Inc. (Hyku), a covalent precision medicine company, today announced the appointment of Kleem Chaudhary, Ph.D. as President and Chief Executive Officer, succeeding co-founder and acting CEO Milind Deshpande, Ph.D. who will now serve as an advisor to the company. Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.

Key Points: 
  • Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.
  • Most recently, he was Chief Operating and Business Officer at Redona Therapeutics.
  • Dr. Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill and a B.Sc.
  • “We are excited to have Kleem join Hyku and I look forward to working with him to advance the exciting science at Hyku.”

German American Bank Announces Scott Powell as Chief Credit Officer

Retrieved on: 
Monday, March 4, 2024

JASPER, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) and its banking subsidiary, German American Bank, announces that Scott Powell has been appointed Executive Vice President, Chief Credit Officer, effective April 1, 2024.

Key Points: 
  • JASPER, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) and its banking subsidiary, German American Bank, announces that Scott Powell has been appointed Executive Vice President, Chief Credit Officer, effective April 1, 2024.
  • Powell will succeed current Executive Vice President and Chief Credit Officer, Keith A. Leinenbach, who will be retiring.
  • As an executive, he has been instrumental in growing our company both organically and through acquisitions, and driving superior financial performance.”
    Powell joined German American Bank through the acquisition of First Security Bank in 2018 where he served as an executive and Chief Credit officer.
  • He currently serves in the role of Regional Credit Officer at German American.

Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development

Retrieved on: 
Monday, March 4, 2024

At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.

Key Points: 
  • At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.
  • Before becoming Head of Clinical Operations at Sitryx, Gordon was Vice President of Development Operations at biotech company Mission Therapeutics, where he oversaw the design and execution of the company’s clinical development assets.
  • Leading Sitryx’s clinical operations, Gordon will work with the development team as it progresses its assets beyond pre-clinical research and into clinical-stage drug development.
  • Dr Ravi Rao, Chief Medical Officer of Sitryx, commented: “Sitryx has made excellent progress with its pipeline of potential first- and best-in-class, disease-modifying therapeutics.

Gevo Hires Damien Perriman as Chief Business Development Officer

Retrieved on: 
Monday, February 26, 2024

ENGLEWOOD, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Damien Perriman has been hired as Chief Business Development Officer to lead the effort to bring in new business in a wider variety of industry sectors and expand the brand footprint for the company.

Key Points: 
  • ENGLEWOOD, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Damien Perriman has been hired as Chief Business Development Officer to lead the effort to bring in new business in a wider variety of industry sectors and expand the brand footprint for the company.
  • Damien is a highly experienced business executive with proven thought leadership and a track record for establishing partnerships with companies looking to engage with disruptive bio-based technologies.
  • He held business development lead roles at Verdezyne and contributed to bioscience ventures at Dow Chemical.
  • "Gevo is in an exciting growth phase, with partners primed to embrace widespread utilization of sustainable resources, be it for fuel or chemicals," Perriman noted.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Tuesday, February 20, 2024

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

RetinAI Discovery® platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists

Retrieved on: 
Tuesday, February 20, 2024

US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.

Key Points: 
  • US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.
  • Discovery for Clinics and its expert-level AI models have been designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions and patient management generating data efficiencies and enhancing decisions for clinics.
  • The vendor neutral and multi-modality platform harmonizes, aggregates, and connects large datasets on a single, cloud-based repository for data.
  • The data is then automatically analyzed with RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms for accelerated and AI-biomarker based treatment decisions.

Raji Manasseh Joins Aristotle Capital Management as a Managing Director, Client Portfolio Manager

Retrieved on: 
Thursday, March 7, 2024

Aristotle Capital Management, LLC (“Aristotle”) today announced an addition to its investment team by appointing Raji Manasseh, CFA, as a Managing Director, Client Portfolio Manager.

Key Points: 
  • Aristotle Capital Management, LLC (“Aristotle”) today announced an addition to its investment team by appointing Raji Manasseh, CFA, as a Managing Director, Client Portfolio Manager.
  • Mr. Manasseh will serve as a primary liaison between the Aristotle Capital Management investment team and its clients and prospects.
  • View the full release here: https://www.businesswire.com/news/home/20240307611643/en/
    Raji Manasseh, Managing Director, Client Portfolio Manager at Aristotle Capital Management (Photo: Business Wire)
    “We are thrilled to welcome Raji to Aristotle,” said Ms. Llinás.
  • Prior to joining PIMCO, he served as Client Portfolio Manager at Goldman Sachs Asset Management (GSAM) for fundamental U.S. growth equity.

VedaBio Strengthens Management Team

Retrieved on: 
Wednesday, March 6, 2024

He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.

Key Points: 
  • He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.
  • “It is a privilege to serve a team that is truly operating at the forefront of scientific innovation, as we work together to create a fundamental new model in the field of molecular detection,” said Fred Sweeney, PhD, President and Chief Executive Officer, VedaBio.
  • “I am continuously impressed by the executive and scientific talent of the VedaBio team.
  • The VedaBio team shares a deep commitment to the mission of revolutionizing molecular detection and to empowering major advances across multiple applications,” said Craig Asher, Lead Director of VedaBio and Managing Director, OMX Ventures.

Laura Hay Named to MetLife’s Board of Directors

Retrieved on: 
Wednesday, February 28, 2024

MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20240227857191/en/
    LAURA HAY NAMED TO METLIFE’S BOARD OF DIRECTORS (Photo: Business Wire)
    Hay was Global Head of Insurance at KPMG LLP prior to her retirement in 2023, where she was an advisor on transformation, growth strategy, customer-focused innovation and risk mitigation to global boards and executive management teams.
  • Hay was a member of the KPMG Global Financial Services Leadership Team and served on KPMG’s U.S. board of directors for five years and the KPMG Americas board for three years.
  • Hay was named an “Inspiring Woman in Finance” in 2022 by the CPCU Society.